Current Value
$574.151 Year Return
Current Value
$574.151 Year Return
Double maintains 9 strategies that include REGN - Regeneron Pharmaceuticals, Inc.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RRGB | -25.84% | $99.85M | -4.90% | 0.00% |
UUU | -18.69% | $7.33M | +132.47% | 0.00% |
ROOT | -11.86% | $2.00B | +63.34% | 0.00% |
MO | -9.68% | $97.92B | +21.81% | 7.02% |
LFMD | -8.22% | $514.47M | +69.21% | 0.00% |
MKTX | -7.52% | $8.15B | -1.09% | 1.39% |
CARV | -6.95% | $9.42M | +22.16% | 0.00% |
PULM | -6.35% | $23.92M | +218.89% | 0.00% |
TZOO | -5.54% | $144.68M | +58.64% | 0.00% |
OR | -5.21% | $5.15B | +57.13% | 0.71% |
ATEC | -5.13% | $1.59B | -4.47% | 0.00% |
UVV | -5.12% | $1.36B | +12.79% | 5.93% |
RLX | -4.53% | $2.15B | +33.33% | 0.43% |
NEXT | -4.41% | $2.93B | +38.35% | 0.00% |
NGVC | -4.32% | $923.29M | +71.92% | 1.16% |
SFM | -4.18% | $16.10B | +96.25% | 0.00% |
AIFU | -4.02% | $17.40M | +87.81% | 0.00% |
LRN | -3.88% | $5.88B | +92.28% | 0.00% |
GFI | -3.54% | $21.69B | +51.82% | 2.28% |
CBOE | -3.17% | $24.71B | +36.77% | 1.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BIIB | 53.70% | $19.50B | -39.93% | 0.00% |
MTD | 46.26% | $24.81B | -12.12% | 0.00% |
RVTY | 45.15% | $11.61B | -8.92% | 0.29% |
SNY | 44.92% | $118.29B | -3.19% | 4.52% |
IQV | 43.86% | $27.70B | -29.11% | 0.00% |
LYB | 42.23% | $20.26B | -34.09% | 8.45% |
ROIV | 41.90% | $7.91B | +1.13% | 0.00% |
COO | 41.76% | $14.69B | -16.98% | 0.00% |
A | 41.42% | $34.11B | -8.34% | 0.84% |
GEHC | 41.32% | $34.09B | -7.16% | 0.17% |
BRKR | 41.23% | $6.55B | -31.86% | 0.46% |
PFE | 41.13% | $144.12B | -12.89% | 6.69% |
LFUS | 41.02% | $5.73B | -12.71% | 1.23% |
ARW | 40.81% | $6.84B | +7.62% | 0.00% |
TMO | 40.78% | $160.56B | -21.91% | 0.39% |
SPB | 40.77% | $1.38B | -31.22% | 3.23% |
KRYS | 40.74% | $4.35B | -27.65% | 0.00% |
IDYA | 40.55% | $1.98B | -45.39% | 0.00% |
APTV | 40.43% | $15.35B | -2.46% | 0.00% |
GAP | 40.37% | $7.99B | -6.66% | 2.97% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
POAI | <0.01% | $7.69M | -27.93% | 0.00% |
MYRG | 0.01% | $2.90B | +28.00% | 0.00% |
VHC | 0.13% | $74.47M | +193.32% | 0.00% |
FARO | 0.14% | $848.40M | +153.29% | 0.00% |
LEU | -0.19% | $3.68B | +357.71% | 0.00% |
EGO | 0.25% | $4.21B | +23.18% | 0.00% |
UNH | -0.31% | $272.67B | -41.68% | 2.84% |
AGI | -0.34% | $11.16B | +51.14% | 0.38% |
HIMS | 0.35% | $11.65B | +127.80% | 0.00% |
QBTS | 0.35% | $4.95B | +1,090.23% | 0.00% |
IMNN | -0.36% | $10.57M | -63.89% | 0.00% |
LNG | -0.36% | $53.57B | +35.95% | 0.81% |
AU | -0.53% | $24.15B | +65.64% | 2.14% |
PHYS.U | -0.53% | - | - | 0.00% |
TLN | 0.60% | $12.83B | +116.38% | 0.00% |
LFVN | 0.61% | $155.84M | +97.76% | 1.32% |
GEO | -0.64% | $3.72B | +50.89% | 0.00% |
SHLS | 0.68% | $961.26M | -15.44% | 0.00% |
PAYC | 0.69% | $12.84B | +42.21% | 0.68% |
DOGZ | -0.71% | $124.63M | -36.05% | 0.00% |
SeekingAlpha
Parnassus Value Equity Fund Q2 2025 Commentary
SeekingAlpha
AnaptysBioâs lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find out why ANAB stock is a hold.
Yahoo
The global ascites market is experiencing significant growth, driven by the rising prevalence of liver diseases, cancers, and other risk factors like alcohol consumption and hepatitis infections. Key advancements in diagnostic technologies, such as ultrasound and CT scans, are enhancing early detection and treatment options. Despite growth, challenges like high treatment costs and potential side effects hinder market expansion, particularly in developing regions. Leading companies, including Oce
Yahoo
Key factors fueling this trend include increased awareness, improved healthcare infrastructure, and enhanced diagnostic and treatment accessibility. With the prevalence of high myopia projected to surpass 1 billion people globally by 2050, the demand for innovative interventions like anti-VEGF therapies is surging. However, the high cost of treatments remains a challenge, particularly in developing regions. Companies such as Regeneron, Roche, and Bayer are driving advances in treatment technolog
Yahoo
The global wet age-related macular degeneration (AMD) market is expanding rapidly due to factors like an aging population, advancements in treatment options, and increased awareness. A leading cause of vision loss in people over 50, wet AMD is primarily treated with anti-VEGF therapies, which dominate the market. Innovations like cell and gene therapy, early detection technologies like OCT, and personalized medicine are shaping the market's future. However, challenges such as high treatment cost
Yahoo
Summary: Options traders seeking to extract quick profits may want to keep an eye on WMB, REGN and IOT this week.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IBB | 63.98% | $5.59B | 0.45% |
BBH | 62.53% | $345.62M | 0.35% |
FBT | 58.54% | $1.05B | 0.54% |
PBE | 56.74% | $233.59M | 0.58% |
XBI | 54.04% | $5.19B | 0.35% |
RSPH | 51.99% | $728.37M | 0.4% |
VHT | 51.46% | $15.49B | 0.09% |
HYXF | 51.21% | $183.42M | 0.35% |
FHLC | 51.04% | $2.46B | 0.084% |
IYH | 50.90% | $2.76B | 0.39% |
PINK | 50.77% | $132.39M | 0.5% |
FXH | 49.79% | $891.10M | 0.62% |
XLV | 49.66% | $34.28B | 0.09% |
IHE | 48.77% | $562.06M | 0.39% |
PPH | 48.70% | $544.00M | 0.36% |
IXJ | 48.09% | $3.80B | 0.41% |
XPH | 48.04% | $155.51M | 0.35% |
GNOM | 45.91% | $45.27M | 0.5% |
MOAT | 45.69% | $12.98B | 0.47% |
SCHD | 43.01% | $71.72B | 0.06% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -29.22% | $200.94M | 0.85% |
TAIL | -27.02% | $94.90M | 0.59% |
VIXM | -26.59% | $22.99M | 0.85% |
BTAL | -21.48% | $310.24M | 1.43% |
IVOL | -14.78% | $341.06M | 1.02% |
XHLF | -14.61% | $1.73B | 0.03% |
CLIP | -12.39% | $1.51B | 0.07% |
BIL | -12.14% | $41.78B | 0.1356% |
XONE | -10.67% | $629.16M | 0.03% |
TBLL | -9.50% | $2.12B | 0.08% |
GBIL | -9.33% | $6.37B | 0.12% |
BOXX | -8.40% | $6.97B | 0.19% |
TPMN | -7.99% | $30.86M | 0.65% |
BILZ | -7.65% | $852.10M | 0.14% |
FXY | -6.69% | $798.58M | 0.4% |
JMST | -6.55% | $4.09B | 0.18% |
AGZD | -6.31% | $98.57M | 0.23% |
SPTS | -5.62% | $5.78B | 0.03% |
BILS | -5.57% | $3.80B | 0.1356% |
VGSH | -4.01% | $22.70B | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
UUP | 0.07% | $183.22M | 0.77% |
USFR | 0.10% | $18.61B | 0.15% |
OILK | 0.11% | $72.70M | 0.69% |
IAU | 0.11% | $47.18B | 0.25% |
TFLO | -0.14% | $6.73B | 0.15% |
IBTF | 0.15% | $1.98B | 0.07% |
BAR | 0.17% | $1.11B | 0.1749% |
CMBS | -0.21% | $456.43M | 0.25% |
GOAU | 0.23% | $124.23M | 0.6% |
KCCA | 0.28% | $109.01M | 0.87% |
STOT | -0.34% | $254.22M | 0.45% |
SGOL | 0.35% | $5.21B | 0.17% |
AAAU | 0.36% | $1.56B | 0.18% |
IBTG | 0.40% | $1.93B | 0.07% |
GLD | 0.44% | $100.91B | 0.4% |
OUNZ | 0.68% | $1.74B | 0.25% |
UGA | 0.69% | $75.20M | 0.97% |
BNO | -0.70% | $108.34M | 1% |
UDN | 0.72% | $147.26M | 0.78% |
SMB | -0.75% | $276.89M | 0.07% |